Our Platforms

Technology platforms to power true precision in oncology testing.1,2

Guardant Complete liquid and tissue biopsies are powered by the Guardant Infinity™ and Guardant Galaxy™ platforms.2,3

Guardant Infinity
Guardant Galaxy
Guardant Infinite Image

Guardant Infinity is the first and only commercially available platform to combine genomic and epigenomic profiling via liquid biopsy to offer a truly multidimensional view of cancer.1


See what’s next now with the Guardant Infinity platform

Download the Guide

SVG Image

In a clinical setting, Guardant products powered by the Infinity platform can have:

  • Even faster turnaround times
    post-sample receipt1

  • Enhanced sensitivity
    with 100x to 1000x more signals
    available to analyze1

  • New insights
    across the continuum of care, from
    minimal residual disease to progression1

Profiling

Precision oncology has advanced our ability to match the right patient to the right treatment at the right time—and we are just getting started.

A new dimension of insights: An epigenomics example1,4

null
null

Genomic profiling offers details into
alterations of the genomic DNA…

null

...while epigenomic profiling can help
detect alterations to the expression of
the genome.4,5

null

The epigenome is a dynamic
landscape providing breakthrough
insights to offer a more complete view
of cancer.4,6,7

SVG Image

An AI-backed algorithm that’s available with the Guardant360
TissueNext™ PD-L1 test to keep you on the cutting edge of PD-L1
detection technology.2

Download the Guide

SVG Image

  • AI-backed digital pathology algorithm that is now validated for multiple cancer types2†

  • Accurate scoring helps to predict response to immunotherapy10

  • Orderable through Guardant360 TissueNext with PD-L1—results in 2 to 3 weeks2

*Compared with genomic-only detection.1
†Guardant360 TissueNext PD-L1 test powered by Guardant Galaxy is available for NSCLC, breast, urothelial, hepatobiliary, gastric, colorectal, pancreatic, and prostate cancers. Some
cases may require conventional determination of PD-L1 status without AI.2
‡Compared to manual pathologist interpretation in the most challenging cases in NSCLC.11
AI, artificial intelligence; MRD, minimal residual disease; PD-L1, programmed death-ligand 1.

References: 1. Guardant Health data on file: Guardant Infinity. Guardant Health, Inc. Redwood City, CA. 2. Guardant Health data on file: Guardant Galaxy. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health data on file: Guardant Reveal on Infinity. Guardant Health, Inc. Redwood City, CA. 4. Muthamilselvan S, Raghavendran A, Palaniappan A. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression. PLoS One.2022;17(2):e0249151. doi:10.1371/journal.pone.0249151 5. NCI Dictionary of Cancer Terms. Definition of Genomic Profiling. Accessed: July 25, 2023. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/genomic-profiling 6. Watts GS, Futscher BW, Holtan N, Degeest K, Dorman FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008;1:47. doi:10.1186/1755-8794-1-47 7. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273-277. doi:10.1038/s41586-019-1618-0 8. Berchuck JE, Baca SC, McClure HM, et al. Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis. Clin Cancer Res. 2022;28(5):929-938. doi:10.1158/1078-0432.CRR-21-3762 9. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018; 9(1):3970. doi:101.1038/s41467-018-05564-z 10. Rodriguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specificed final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881-895. doi:10.1016/j.annonc.2021/04.008 11. Choi S, Cho SI, Ma M, et al. Artifical intelligence—powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. Eur J Cancer. 2022;170:17-26. doi:10.1016/j.ejca.2022.04.011